

Skin barrier dysfunction

Inflammation

Irregular pigmentation

Wrinkle formation

Description


As a newly developed peptidomimetic with strong antioxidant and autophagy stimulating activity, ICP De-AGE 1 has dual mode of actions against skin AGEs (advanced glycation end products); slowdown of AGEs generation and boosting of preformed AGEs elimination.

ICP De-AGE 1 can improve all of the AGE-induced skin deformity, including mechanical and physiological damages in skin, as well as irregular pigmentation and dullness, ultimately helps to delay skin AGEing.


Biological activity and efficacy

Prevention of AGEs formation with anti-oxidant activity


Anti-oxidant activity



Prevention of AGE formation




Prevention of AGE formation (keratinocytes)




Glucose (25mM) + Glyoxal (10mM)

Acceleration of pre-formed AGEs elimination




Skin Soothing Activities



Ex vivo effcacy


Reduction of AGEs in Skin



■ Green: AGEs (advanced glycation end-products)

■ Dotted line: dermal-epidermal junction

Glycation inducer (1 mM of methylglyoxal)






Normal skin

Reduction of RAGE in Skin

Glycation inducer (1 mM of methylglyoxal)



■ Green: RAGE (receptor for AGEs) ■ Dotted line : dermal-epidermal junction

Soothing Effects

Normal skin

Glycation inducer (1 mM of methylglyoxal)








UV + ICP De-AGE1

Anti-wrinkle Effects

Normal skin

■ Blue : Collagen

■ Red: cytoplasm





UV (50mJ/cm2)

UV + ICP De-AGE1

PCPC/INCI Name N-Dichloroacetyl Tryptamine

■ Green: inflammation marker protein (interleukin-6)

Recommended dosage 1 ~ 2%

■ Dotted line: dermal-epidermal junction

Application Skin soothing and calming, Anti-AGEing, Anti-wrinkle, anti-oxidant

Patent No KR10-1667215 Composition ICP De-AGE I 1000ppm

